BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38453679)

  • 21. Degenerative and inflammatory markers in the cerebrospinal fluid of multiple sclerosis patients with relapsing-remitting course of disease and after clinical isolated syndrome.
    Sladkova V; Mareš J; Lubenova B; Zapletalova J; Stejskal D; Hlustik P; Kanovsky P
    Neurol Res; 2011 May; 33(4):415-20. PubMed ID: 21535941
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebrospinal fluid interleukin-6 in central nervous system inflammatory diseases.
    Wullschleger A; Kapina V; Molnarfi N; Courvoisier DS; Seebach JD; Santiago-Raber ML; Hochstrasser DF; Lalive PH
    PLoS One; 2013; 8(8):e72399. PubMed ID: 24015240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis.
    Sellebjerg F; Royen L; Soelberg Sørensen P; Oturai AB; Jensen PEH
    Mult Scler; 2019 Oct; 25(11):1444-1451. PubMed ID: 30113249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis.
    Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
    Eur J Neurol; 2017 May; 24(5):703-712. PubMed ID: 28261960
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis.
    Hinsinger G; Galéotti N; Nabholz N; Urbach S; Rigau V; Demattei C; Lehmann S; Camu W; Labauge P; Castelnovo G; Brassat D; Loussouarn D; Salou M; Laplaud D; Casez O; Bockaert J; Marin P; Thouvenot E
    Mult Scler; 2015 Sep; 21(10):1251-61. PubMed ID: 25698171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of candidate biomarkers in converting and non-converting clinically isolated syndrome by proteomics analysis of cerebrospinal fluid.
    Timirci-Kahraman O; Karaaslan Z; Tuzun E; Kurtuncu M; Baykal AT; Gunduz T; Tuzuner MB; Akgun E; Gurel B; Eraksoy M; Kucukali CI
    Acta Neurol Belg; 2019 Mar; 119(1):101-111. PubMed ID: 29873030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of free light chains lambda and kappa in early multiple sclerosis.
    Voortman MM; Stojakovic T; Pirpamer L; Jehna M; Langkammer C; Scharnagl H; Reindl M; Ropele S; Seifert-Held T; Archelos JJ; Fuchs S; Enzinger C; Fazekas F; Khalil M
    Mult Scler; 2017 Oct; 23(11):1496-1505. PubMed ID: 27899552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fatigue scores correlate with other self-assessment data, but not with clinical and biomarker parameters, in CIS and RRMS.
    Håkansson I; Johansson L; Dahle C; Vrethem M; Ernerudh J
    Mult Scler Relat Disord; 2019 Nov; 36():101424. PubMed ID: 31586802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subclinical central inflammation is risk for RIS and CIS conversion to MS.
    Rossi S; Motta C; Studer V; Macchiarulo G; Germani G; Finardi A; Furlan R; Martino G; Centonze D
    Mult Scler; 2015 Oct; 21(11):1443-52. PubMed ID: 25583841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Decreased levels of alpha-synuclein in cerebrospinal fluid of patients with clinically isolated syndrome and multiple sclerosis.
    Antonelou RCh; Emmanouilidou E; Gasparinatos G; Velona T; Voumvourakis KI; Stefanis L
    J Neurochem; 2015 Aug; 134(4):748-55. PubMed ID: 25962981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sulfatide isoform pattern in cerebrospinal fluid discriminates progressive MS from relapsing-remitting MS.
    Novakova L; Singh AK; Axelsson M; Ståhlman M; Adiels M; Malmeström C; Zetterberg H; Borén J; Lycke J; Cardell SL; Blomqvist M
    J Neurochem; 2018 Aug; 146(3):322-332. PubMed ID: 29676479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum and cerebrospinal fluid prolactin levels in male and female patients with clinically-isolated syndrome or relapsing-remitting multiple sclerosis.
    Markianos M; Koutsis G; Evangelopoulos ME; Mandellos D; Sfagos C
    J Neuroendocrinol; 2010 Jun; 22(6):503-8. PubMed ID: 20236233
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oxylipins in cerebrospinal fluid in clinically isolated syndrome and relapsing remitting multiple sclerosis.
    Håkansson I; Gouveia-Figueira S; Ernerudh J; Vrethem M; Ghafouri N; Ghafouri B; Nording M
    Prostaglandins Other Lipid Mediat; 2018 Sep; 138():41-47. PubMed ID: 30118859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression.
    Teunissen CE; Sombekke M; van Winsen L; Killestein J; Barkhof F; Polman CH; Dijkstra CD; Blankenstein MA; Pratico D
    Mult Scler; 2012 Aug; 18(8):1092-8. PubMed ID: 22695538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CSF CXCL13 and Chitinase 3-like-1 Levels Predict Disease Course in Relapsing Multiple Sclerosis.
    Lucchini M; De Arcangelis V; Piro G; Nociti V; Bianco A; De Fino C; Di Sante G; Ria F; Calabresi P; Mirabella M
    Mol Neurobiol; 2023 Jan; 60(1):36-50. PubMed ID: 36215027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis.
    Novakova L; Axelsson M; Khademi M; Zetterberg H; Blennow K; Malmeström C; Piehl F; Olsson T; Lycke J
    Mult Scler; 2017 Jan; 23(1):62-71. PubMed ID: 27003946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cerebrospinal fluid levels of CXCL13 are elevated in neuromyelitis optica.
    Zhong X; Wang H; Dai Y; Wu A; Bao J; Xu W; Cheng C; Lu Z; Qiu W; Hu X
    J Neuroimmunol; 2011 Dec; 240-241():104-8. PubMed ID: 22036953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utility of chemokines CCL2, CXCL8, 10 and 13 and interleukin 6 in the pediatric cohort for the recognition of neuroinflammation and in the context of traditional cerebrospinal fluid neuroinflammatory biomarkers.
    Liba Z; Nohejlova H; Capek V; Krsek P; Sediva A; Kayserova J
    PLoS One; 2019; 14(7):e0219987. PubMed ID: 31356620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The alterations of cerebrospinal fluid TNF-alpha and TGF-beta2 levels in early relapsing-remitting multiple sclerosis.
    Grzegorski T; Iwanowski P; Kozubski W; Losy J
    Immunol Res; 2022 Oct; 70(5):708-713. PubMed ID: 35729473
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebrospinal fluid biomarkers for predicting development of multiple sclerosis in acute optic neuritis: a population-based prospective cohort study.
    Olesen MN; Soelberg K; Debrabant B; Nilsson AC; Lillevang ST; Grauslund J; Brandslund I; Madsen JS; Paul F; Smith TJ; Jarius S; Asgari N
    J Neuroinflammation; 2019 Mar; 16(1):59. PubMed ID: 30857557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.